Hui Jing Hong

Ms. Hui Jing Hong

INFORMM, Universiti Sains Malaysia, George Town, Pulau Pinang, Malaysia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Hui Jing HongHui Jing Hong
Hui Jing Hong
Fevzi BardakciFevzi Bardakci
Fevzi Bardakci
SASinan Akgol
Sinan Akgol
KKKevser Kuşat
Kevser Kuşat
Mohd AdnanMohd Adnan
Mohd Adnan
SSSreenivasan Sasidharan
Sreenivasan Sasidharan
Carbon dots (CDs) are a new category of crystalline, quasi-spherical fluorescence, “zero-dimensional” carbon nanomaterials with a spatial size between 1 nm to 10 nm and have gained widespread attention in recent years. Green CDs are carbon dots synthesised from renewable biomass such as agro-waste, plants or medicinal plants and other organic biomaterials. Plant-mediated synthesis of CDs is a green chemistry approach that connects nanotechnology with the green synthesis of CDs. Notably, CDs made with green technology are economical and far superior to those manufactured with physicochemical methods due to their exclusive benefits, such as being affordable, having high stability, having a simple protocol, and being safer and eco-benign. Green CDs can be synthesized by using ultrasonic strategy, chemical oxidation, carbonization, solvothermal and hydrothermal processes, and microwave irradiation using various plant-based organic resources. CDs made by green technology have diverse applications in biomedical fields such as bioimaging, biosensing and nanomedicine, which are ascribed to their unique properties, including excellent luminescence effect, strong stability and good biocompatibility. This review mainly focuses on green CDs synthesis, characterization techniques, beneficial properties of plant resource-based green CDs and their biomedical applications. This review article also looks at the research gaps and future research directions for the continuous deepening of the exploration of green CDs.

5 February 2024 in Journal of Advanced Research
Verified
Journal Article
Open access
Hui Jing HongHui Jing Hong
Hui Jing Hong
ASAli A. Shati
Ali A. Shati
MAMohammad Alfaifi
Mohammad Alfaifi
SESerag Eldin I. Elbehairi
Serag Eldin I. Elbehairi
SSSreenivasan Sasidharan
Sreenivasan Sasidharan
The emergence of carbon dots (CDs) as anticancer agents had sparked a transformation in cancer research and treatment strategies. These fluorescent CDs, initially introduced in the early 2000 s, possess exceptional biocompatibility, tunable fluorescence, and surface modification capabilities, positioning them as promising tools in biomedical applications. The review encapsulates the transformative trajectory of green CDs as future anticancer nanomedicine, poised to redefine the strategies employed in the ongoing fight against cancer. The versatility of CDs was rooted in their various synthesis approaches and sustainable strategies, enabling their adaptability for diverse therapeutic uses. In vitro studies had showcased CDs' selective cytotoxicity against cancer cells while sparing healthy counterparts, forming the basis for targeted therapeutic potential. This selectivity had been attributed to the reactive oxygen species (ROS) generation, which opened avenues for targeted interventions. The role of CDs in combination therapies, synergizing with chemotherapy, radiotherapy, and targeted approaches was then investigated to heighten their anticancer efficacy. Notably, in vivo studies highlight CDs' remarkable biocompatibility and minimal side effects, endorsing their translational promise. Integration with conventional cancer treatments such as chemotherapy, radiotherapy, and immunotherapy amplified the versatility and effectiveness of CDs. The exploration of CDs' applications in photo-induced treatments further solidified their significance, positioning them as photosensitizers (PS) in photodynamic therapy (PDT) and photothermal agents (PA) in photothermal therapy (PTT). In PDT, CDs triggered the generation of ROS upon light exposure, facilitating cancer cell elimination, while in PTT, they induced localized hyperthermia within cancer cells, enhancing therapeutic outcomes. In vitro and in vivo investigations validated CDs' efficacy in PDT and PTT, affirming their potential for integration into combination therapies. Looking ahead, the future of CDs in anticancer treatment encompasses bioavailability, biocompatibility, synergistic treatments, tumor targeting, artificial intelligence (AI) and robotics integration, personalized medicine, and clinical translation. This transformative odyssey of CDs as future anticancer agents is poised to redefine the paradigm of cancer treatment strategies.

1 September 2022 in Food Science and Human Wellness
Verified
Journal Article
Open access
JWJia Fei Wong
Jia Fei Wong
Hui Jing HongHui Jing Hong
Hui Jing Hong
SFSu Chern Foo
Su Chern Foo
MYMichelle Khai Khun Yap
Michelle Khai Khun Yap
JTJi Wei Tan
Ji Wei Tan

20 November 2025 in Journal of the National Cancer Center
Verified
Journal Article
Open access
Hui Jing HongHui Jing Hong
Hui Jing Hong
Patel MiteshPatel Mitesh
Patel Mitesh
Mohd AdnanMohd Adnan
Mohd Adnan
SSSreenivasan Sasidharan
Sreenivasan Sasidharan
Carbon dots (CDs) have emerged as promising nanomaterials in cancer phototherapy due to their unique optical properties, biocompatibility, and tunability. This review comprehensively examines the role of CDs in photodynamic therapy (PDT) and photothermal therapy (PTT), highlighting their mechanisms of action, including the induction of apoptosis, necrosis, and necroptosis in cancer cells. Key factors influencing the efficacy of cancer phototherapy—such as the tumor microenvironment (TME), nanoparticle stability, and light parameters—are thoroughly analyzed. Advancements in surface modifications, targeted, drug delivery and multifunctional applications, including their integration with chemotherapy and immunotherapy, further expand the clinical potential of CDs. While preclinical studies have demonstrated the efficacy of CDs in selectively targeting cancer cells and inducing therapeutic effects, challenges related to biosafety and regulatory approval hinder clinical translation. By addressing existing challenges and leveraging interdisciplinary innovations, CDs hold great promise for personalized and less invasive cancer treatments. Their future success in clinical application will depend on overcoming biological barriers and optimizing the safety profile to facilitate their seamless integration into oncology.